Nastech [NSTK] -Sm & Lrg Molecule Intranasal drug delivery Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nastech [NSTK] -Sm & Lrg Molecule Intranasal drug delivery

MRNA 44.07

-6.0%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: nigel bates	6/7/2006 2:52:02 PM
	Read Replies (1) of 80

Nastech Submits Investigational New Drug Application for PYY3-36 Nasal Spray to Treat Obesity BOTHELL, Wash., June 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK - News) announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for PYY3-36 (PYY) nasal spray, the company's lead investigational product candidate for treatment of obesity. The filing of the IND precedes the initiation of clinical studies in the United States. The study included in the IND is designed to evaluate the pharmacokinetic parameters, appetite, food intake and safety of various dosing regimens of PYY nasal spray in obese subjects. The objective of study is to determine the optimal dosing regimens that will be used to conduct a Phase II clinical study based on the successful completion of this initial trial. "We're moving aggressively to demonstrate the potential for PYY nasal spray to treat obesity," stated Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech. "We have been working with recognized experts in the obesity field to design the appropriate clinical trial program for this exciting candidate. Positive Phase II safety and efficacy data would be the basis for establishing a collaboration with a major pharmaceutical company for the remaining development and commercialization of PYY nasal spray." About PYY Peptide YY is a naturally occurring hormone that is believed to function as a physiologic inhibitor of food intake. PYY is produced by specialized endocrine cells (L-cells) in the gut after a person eats and is believed to trigger the feeling of satiety, or fullness. Because PYY is a protein, initial studies focused on PYY delivery by injection. Utilizing its proprietary drug delivery technology, Nastech developed the nasal spray formulation of PYY as a unique, non-invasive treatment option for obesity.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next